Wrobel, Lidia http://orcid.org/0000-0002-5127-5616
Hill, Sandra M. http://orcid.org/0000-0001-7969-097X
Djajadikerta, Alvin http://orcid.org/0000-0002-6827-2817
Fernandez-Estevez, Marian
Karabiyik, Cansu
Ashkenazi, Avraham http://orcid.org/0000-0002-1253-497X
Barratt, Victoria J.
Stamatakou, Eleanna
Gunnarsson, Anders
Rasmusson, Timothy
Miele, Eric W.
Beaton, Nigel
Bruderer, Roland
Feng, Yuehan
Reiter, Lukas
Castaldi, M. Paola
Jarvis, Rebecca
Tan, Keith
Bürli, Roland W.
Rubinsztein, David C. http://orcid.org/0000-0001-5002-5263
Funding for this research was provided by:
UK Dementia Research Institute
Article History
Received: 11 October 2021
Accepted: 8 July 2022
First Online: 16 July 2022
Competing interests
: E.W.M., T.R., M.P.C., A.G., K.T., R.J., and R.W.B. were employees of AstraZeneca when the experiments were performed and are shareholders of AstraZeneca. R.W.B. is currently employed by Cerevance Ltd. T.R. is currently employed by Monte Rosa Therapeutics. M.P.C. is currently employed by LifeMine Therapeutics. M.F.E. is currently employed by GW Research Ltd. N.B., R.B., Y.F., and L.R. are employees of Biognosys A.G. D.C.R. is a consultant for Alladdin Healthcare Technologies Ltd., Mindrank AI, Nido Biosciences, Drishti Discoveries, and PAQ Therapeutics. None of the other authors have competing interests.